300147 *ST香雪制药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入354,160-15.88%1,595,4071,858,6622,299,2882,187,070
减:营业总成本401,280-17.09%1,970,9412,266,7422,452,4742,575,669
    其中:营业成本228,495-23.21%1,159,4681,405,8071,509,5211,643,173
               财务费用68,67123.58%276,612231,011241,471212,510
               资产减值损失(1,932)-79.12%(544,408)(380,109)(163,342)(138,578)
公允价值变动收益87-91.57%(780)6362,728(12)
投资收益(428)-155.37%(835)(6,000)(50,640)47,329
    其中:对联营企业和合营企业的投资收益(428)126.37%(984)(1,343)(52,159)903
营业利润(43,099)-34.81%(922,598)(784,525)(332,716)(464,142)
利润总额(89,196)13.34%(1,336,835)(842,071)(388,951)(511,864)
减:所得税费用9,140564.46%33,94919,15412,795(7,215)
净利润(98,336)22.81%(1,370,785)(861,224)(401,746)(504,648)
减:非控股权益13,10571.08%21,386(2,664)(12,782)25,410
股东净利润(111,441)27.02%(1,392,171)(858,560)(388,964)(530,058)

市场价值指针
每股收益 (元) *-0.17030.77%-2.110-1.300-0.590-0.800
每股派息 (元) *------------
每股净资产 (元) *-0.713-148.75%-0.5451.5952.9113.637
审计意见 #----标准的无保留意见保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容